TP53 and prostate cancer: We performed single-cell transcriptomic trajectory analyses on a time course of tumor collections from a recently published12 genetically engineered mouse model (GEMM) of prostate cancer that recapitulates the adenocarcinoma-to-NEPC transition after prostate-specific deletion of the tumor suppressor genes PTEN, RB1, and TP53 using CRE recombinase, Pten−/−Rb−/−Trp53−/− (PtRP) (Fig. 4b–e), and leveraged our trajectory analyses for the DKO LnCap/AR model (Fig. 3e).